Octahydro-1H-pyrido<1,2-c>pyrimidin | 4430-81-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: Octahydro-1H-pyrido<1,2-c>pyrimidin
• 英文别名: 2,3,4,4a,5,6,7,8-Octahydro-1H-pyrido<1,2-c>pyrimidin；octahydro-pyrido[1,2-c]pyrimidine；Octahydro-pyrido[1,2-c]pyrimidin；1,3-Diazabicyclo[4.4.0]-decane；2,3,4,4a,5,6,7,8-octahydro-1H-pyrido[1,2-c]pyrimidine
• CAS: 4430-81-3
• 化学式: C₈H₁₆N₂
• 分子量: 140.228
• InChiKey: DEQPFAOVISNVNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 lithium aluminium tetrahydride 作用下， 生成 Octahydro-1H-pyrido<1,2-c>pyrimidin
  参考文献：
  名称：

  Winterfeld; Goebel, Chemische Berichte, 1959, vol. 92, p. 637,641

  摘要：

  DOI：

文献信息

• [EN] 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PIPÉRIDINE 1,4-SUBSTITUÉS
  申请人：CEPHALON INC

  公开号：WO2016205633A1

  公开（公告）日：2016-12-22

  Described herein are 1,4-substituted piperidine compounds according to Formula (I) that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

  本文描述了按照式（I）的1,4-取代哌啶化合物，这些化合物已经表现出作为脂肪酸合成酶抑制剂的活性。本文还描述了含有所述1,4-取代哌啶化合物的药物组合物，以及通过给予所述化合物或药物配方中的一个或多个来治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述化合物的方法，包括所述的1,4-取代哌啶化合物和在这些合成中有用的合成中间体。
• [EN] 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS<br/>[FR] 3- ET 6-QUINOLINES AVEC ANTAGONISTES DE RÉCEPTEURS DE PEPTIDES ASSOCIÉS AU GÈNE DE LA CALCITONINE HÉTÉROCYCLIQUE À N LIAISONS
  申请人：MERCK SHARP & DOHME

  公开号：WO2010021919A1

  公开（公告）日：2010-02-25

  Compounds of Formula (I): (where variables R1A, R1B, R2, R3, R4, A, and Z are as defined herein) which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP receptors are involved.

  公式（I）的化合物：（其中变量R1A、R1B、R2、R3、R4、A和Z的定义如下），这些化合物可用作CGRP受体的拮抗剂，并且在治疗或预防涉及CGRP受体的疾病方面具有用处，例如头痛，特别是偏头痛和集群头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及CGRP受体的这类疾病中的用途。
• [EN] CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEURS DE CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2010107605A1

  公开（公告）日：2010-09-23

  Compounds of Formula (I) (wherein variables A1, A2, A3, ring-B, m, n, J, E1, E2, E3, R5, RPG and Y are as described herein), which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and the use of these compounds and compositions in the prevention or treatment of diseases in which CGRP receptors are involved.

  公式（I）的化合物（其中变量A1、A2、A3、环B、m、n、J、E1、E2、E3、R5、RPG和Y如本文所述），这些化合物可用作CGRP受体的拮抗剂，并可用于治疗或预防涉及CGRP受体的疾病，如头痛，特别是偏头痛和群集性头痛。该发明还涉及包含公式（I）化合物的制药组合物以及在涉及CGRP受体的疾病的预防或治疗中使用这些化合物和组合物的用途。
• Heterocyclic compounds for the treatment of migraine
  申请人：NPS ALLELIX BIOPHARMACEUTICALS, INC.

  公开号：US20040167158A1

  公开（公告）日：2004-08-26

  Described herein are compounds useful in the treatment of migraine, which have the general formula: 1 wherein: W is a CH group or a N atom; Z is N or C-R4; B and D are selected independently from CH and N, with the proviso that at least one of B and D is CH and with the further proviso that one of B and D can represent N only when W and Z are both other than N; A is a group of Formula II, III or IV, such that group A contains at least 1 N atom; NR7 is either —NH— or —N═ is a single or double bond; X is a N atom, a CH group or a C(OH) group when is a single bond; or, when is a double bond, a C atom; Y is an NH, N-alkyl, N-benzyl or CH 2 group; U and V each represent a N atom or a CH group, with the proviso that both cannot be N; a and b are, independently, 0 or 1; c is an integer from 0 to 3; d is an integer from 1 to 3; e is an integer from 1 to 2; f is an integer from 0 to 3; g is an integer from 3 to 6 and h is an integer from 2 to 3; such that the sum of c and d is at least 2 and the sum of e and f is at least 2; R 1 is selected from the group consisting of H, alkyl, alkyloxy, alkanoyl, aminoalkylenyl, alkylaminoalkylenyl, a hydroxyalkylenyl group, an alkyloxyalkylenyl group, a cycloalkyl group, a cycloalkylalkylenyl group, a heterocycloalkyl group, a heterocycloalkylalkylenyl group, an aryl group, a heterocycloaryl group, an amido group, a thioamido group, an arylcarbonyl group and an arylsulfonyl group; R 2 and R 3 are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl and optionally-substituted benzyl; or R 2 and R 3 , together with the nitrogen atom to which they are attached, may form a mono- or bi-cyclic group containing up to 10 carbon atoms and which, in addition, may contain a second heteroatom selected from the group consisting of N, S and O, and which may contain one or more substituents selected from the group consisting of alkyl, hydroxy, hydroxymethyl, alkyloxymethyl, amino and substituted amino; R 4 is selected from the group consisting of H, alkyl and cycloalkyl; CR 5 represents a group selected from —CH2—, CH(OH)—, —C(O)—, —CH(alkyl)- and —CH(alkyloxy)-; R6 is selected from the group consisting of H, alkyl, aryl, halogen, hydroxy, alkyloxy, amino, monoalkylamino and di-substitutedalkylamino; and salts and solvates thereof

  本文描述了治疗偏头痛的化合物，其具有以下通式：1其中：W是CH基团或N原子；Z是N或C-R4；B和D独立地选自CH和N，但至少其中之一为CH，并进一步规定当W和Z都不是N时，B和D中的一个可以表示N；A是公式II、III或IV的基团，使得基团A至少包含1个N原子；NR7是—NH—或—N═；is a single or double bond；当is a double bond时，X是C原子；Y是NH、N-烷基、N-苯甲基或CH2基团；U和V分别表示N原子或CH基团，但两者不能同时为N；a和b独立地为0或1；c是0到3之间的整数；d是1到3之间的整数；e是1到2之间的整数；f是0到3之间的整数；g是3到6之间的整数；h是2到3之间的整数；使得c和d的和至少为2，e和f的和至少为2；R1选自H、烷基、烷氧基、烷酰基、氨基烷基亚烷基、烷基氨基烷基亚烷基、羟基烷基亚烷基、烷氧基烷基亚烷基、环烷基、环烷基烷基亚烷基、杂环烷基、杂环烷基烷基亚烷基、芳基、杂环芳基、酰胺基、硫酰胺基、芳基羰基和芳基磺酰基的群；R2和R3独立地选自H、烷基、环烷基、烯基和可选取代苄基的群；或者R2和R3与它们所连接的氮原子一起，可以形成一个含有最多10个碳原子的单环或双环基团，此外，该基团还可以含有从N、S和O组成的第二个杂原子，以及从烷基、羟基、羟甲基、烷氧甲基、氨基和取代氨基的群中选择的一个或多个取代基；R4选自H、烷基和环烷基；CR5表示选自— —、CH(OH)—、—C(O)—、—CH(烷基)-和—CH(烷氧基)-的基团；R6选自H、烷基、芳基、卤素、羟基、烷氧基、氨基、单烷基氨基和二取代烷基氨基的群；以及其盐和溶剂络合物。
• COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF
  申请人：Hanada Keisuke

  公开号：US20090325992A1

  公开（公告）日：2009-12-31

  A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

  化合物的一般式（I）所代表的化合物，其盐、溶剂化物或前药，其中所有符号均如规范中定义的那样，具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病的药物，例如炎症和免疫性疾病（例如类风湿性关节炎、关节炎、视网膜病变、黄斑变性、肺纤维化、移植器官排斥等）、过敏性疾病、感染（例如人类免疫缺陷病毒感染、获得性免疫缺陷综合症等）、精神神经疾病、脑部疾病、心血管疾病、代谢性疾病、癌症（例如癌症、癌症转移等）的预防和/或治疗药物，或作为再生疗法的药物。